COMPLETE LISTING OF ALL CLAIMS IN THE APPLICATION

1. (previously presented) A process for producing an oral dosage form with sustained realease of active ingredient, comprising

   a) a formulated mixture of polyvinyl acetate and polyvinylpyrrolidone

   b) at least one active ingredient

   c) optionally water-soluble polymers or low or high molecular weight lipophilic additives

   d) and, optionally, excipients,

   wherein the mixture of a) to d) or a) to c) or a) and b) and d) or a) and b) is granulated by heating to from 40° to 130°C, and

   wherein the molecular weight of polyvinylpyrrolidone is between 20,000 and 10,000,000 and wherein the formulated mixture of polyvinylacetate and polyvinylpyrrolidone acts as binder and a matrix former.

2. (previously presented) A process as claimed in claim 1, wherein the polyvinyl acetate to polyvinylpyrrolidone ratio is 6:4 to 9:1.

3. (previously presented) A process as claimed in claim 1, wherein the active ingredient: water-soluble polymers or low or high molecular weight lipophilic additives ratio employed is from 5:95 to 85:15.

4. (previously presented) A process as claimed in claim 1, wherein the polyvinyl acetate and polyvinylpyrrolidone each have a molecular weight of from 20,000 to 1,000,000.

5. (previously presented) A process as claimed in claim 1, wherein the mixture is granulated by heating to from 45 to 100°C.

6. (previously presented) A process as claimed in claim 1, wherein the particle size of the active ingredients employed is in a range from 20 to 700 µm.

7. (previously presented) A process as claimed in claim 1, wherein the excipients employed are fillers, disintegrants and adsorbents, lubricants, flowability agents, dyes, stabilizers, antioxidants, wetting agents, preservatives, release agents, flavorings or sweeteners.

8. (previously presented) A process as claimed in claim 1, wherein fillers are selected from the group consisting of lactose, cellulose powder, mannitol, calcium diphosphate and starch are employed as excipients.

9. (previously presented) A process as claimed in claim 1, wherein the granules can be produced by employing the process of mixer granulation, fluidized bed granulation or extrusion granulation.

10. (previously presented) A process as claimed in claim 1, wherein production is possible both continuously and batchwise.

11. (previously presented) A process as claimed in claim 1, wherein further processing of the granules, principally the forced screening, can take place both in the hot state and in the cooled state.

12. (previously presented) A process as claimed in claim 1, wherein besides the formulated mixture of polyvinyl acetate and polyvinylpyrrolidone, further release-

sustaining excipients may optionally be employed before, during or after the granulation.

13. (previously presented) A process as claimed in claim 1, wherein water-soluble, water-soluble highly swelling or lipophilic excipients are employed for further modification of release.

14. (previously presented) A process as claimed in claim 1, wherein the water-soluble highly swelling substances employed are alginates, pectins, galactomannans, carrageenans, dextran, curdlan, pullulan, gellan, chitin, gelatin, xanthans, hemicelluloses, cellulose derivatives such as methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, carboxymethylcellulose, starch derivatives such as carboxymethylstarch, degraded starch, maltodextrins, polyacrylic acid, polymethacrylic acid, acrylic acid/methacrylic acid copolymers, polyvinyl alcohols, high molecular weight polyethylene glycols, polyoxyethylene/polyoxypropylene block copolymers, high molecular weight polyvinylpyrrolidones and derivatives thereof.

15. (previously presented) A process as claimed in claim 1, wherein the lipophilic substances employed are fatty alcohols consisting of stearyl alcohol, fatty acids selected from the group consisting of such as stearic acid, glycerides, fatty acid esters and fatty alcohol esters, lipophilic polymers selected from the group consisting of ethylcellulose, cellulose acetate, acrylic ester/methacrylic ester copolymers, methacrylic acid/acrylic ester copolymers, cellulose acetate

phthalate, cellulose acetate succinate, hydroxypropylmethylcellulose acetate phthalate and hydroxypropylmethylcellulose acetate succinate.

16. (previously presented) A process as claimed in claim 1, wherein the water-soluble polymers are selected from the group of: polyvinyl alcohols, polyethylene glycols, polyoxyethylene/polyoxypropylene block copolymers, polyvinylpyrrolidones vinyl acetate/vinyl pyrrolidone copolymers, polyethylene glycols, polyvinylpyrrolidones, vinyl acetate/vinylpyrrolidone copolymers or maltodextrins, and salts thereof.

17. (previously presented) An oral dosage form comprising

a) a formulated mixture of polyvinyl acetate and polyvinylpyrrolidone

b) at least one active ingredient

c) optionally water-soluble polymers or low or high molecular weight lipophilic additives

d) and, opitonally excipients,

wherein the mixture of a) to d) or a) to c) or a) and b) and d) or a) and b) is granulated by heating to from 40%C to 130°C

18. (previously presented) An oral dosage form as claimed in claim 17, which comprises as active ingredients food supplements or additives, vitamins, minerals or trace elements or active pharmaceutical ingredients.

19. (previously presented) An oral dosage form as claimed in claim 18, which comprises active pharmaceutical ingredients as active ingredients.

20. (previously presented) An oral dosage form as claimed in claim 18, wherein the active pharmaceutical ingredient is selected from the group of benzodiazepines, antihypertensives, vitamins, cytostatics, anesthetics, neuroleptics, antidepressants, antibiotics, antimycotics, fungicides, chemotherapeutics, urologicals, platelet aggregation inhibitors, sulfonamides, spasmolytics, hormones, immunoglobulins, sera, thyroid therapeutics, psychopharmaceuticals, antiparkinson agents and other antihyperkinetics, ophthalmologicals, neuropathy products, calcium metabolism regulators, muscle relaxants, lipid-lowering agents, liver therapeutics, coronary agents, cardiac agents, immunotherapeutics, regulatory peptides and their inhibitors, hypnotics, sedatives, gynecologicals, antigout agents, fibrinolytics, enzyme products and transport proteins, enzyme inhibitors, emetics, perfusion promoters, diuretics, diagnostics, corticoids, cholinergics, biliary therapeutics, antiasthmatics, bronchospasmolytics, beta-receptor blockers, calcium channel blockers, ACE inhibitors, arteriosclerosis remedies, antiinflammatory agents, anticoagulants, antihypotensives, antihypoglycemics, antifibrinolytics, antiepileptics, antiemetics, antidotes, antidiabetics, antiarrhythmics, antianemics, antiallergics, anthelmintics, analgesics, analeptics, aldosterone antagonists, weight-reducing agents.

21. (previously presented) An oral dosage form as claimed in claim 17, which is used to produce compressed tablets.

22. (previously presented) A drug product with delayed release of active ingredient,

which is an oral dosage form as claimed in claim 17.

23. (previously presented) A drug product for delayed release of active ingredient, which is an oral dosage form as claimed in claim 17 which has been produced by compression.

24. (previously presented) The method of delaying the release of an active ingredient comprising producing the oral dosage forms of claim 17 as drug products.

25. (previously presented) The method of delaying the release of at least one active ingredient comprising producing the oral dosage form of claim 17 wherein the at least one active ingredient comprises food supplements or additives, vitamins, minerals or trace elements.